As the presidential election draws ever nearer, the debate over how to address the rising cost of prescription drugs and provide healthcare coverage for all continues to rage. President Trump plans to unveil his healthcare plan soon. Governor Abbott of Texas has signed into law a measure to prevent
This week’s Innovation Partners BioBlog offers unique perspectives on the issues facing the healthcare industry today. Some CEOs, for example, believe that a “Medicare for all” type of health insurance system would improve the economy by decoupling health insurance from the cost of hiring workers.
The annual ASCO Meeting, held in Chicago, May 31-June 4, 2019, explored many issues related to oncology. Exciting developments in the field of early detection include Grail’s liquid biopsy test and data showing that Medicaid expansion helped detect more cases of ovarian cancer earlier, potentially
This week’s Innovation Partners BioBlog looks at top stories from the world of pharmaceutical and healthcare news. Elderly people who survive the three most common types of cancer are at an increase for brain metastasis, according to a new report. The Trump Administration continues to push for the
Discussions in the news this week circle around CAR-T payments, PBM rebates, and whether or not the Trump Administration will continue voluntary payment models. A new blockchain healthcare initiative demonstrates how the Internet of Things (IoT), blockchain, and healthcare can work together for
Activity at the state and federal level this week is heating up in the fight against higher drug and healthcare costs. PBMs testified before federal lawmakers, who seemed uncertain of their role in the industry. The Montana Senate delayed the Medicaid bill, and Pennsylvania’s Attorney General filed
Debates continue in the government’s quest to push down the cost of prescription drugs as two new treatments, one for postpartum depression and another for depression hit the market with high price tags. Others are tackling “surprise” medical bills, but the ramifications are problematic. These
Nationwide, Congress, insurers, and others continue to wrestle with the costs of healthcare. What is good for some consumers may be bad for others, and a bipartisan coalition is asking the Trump Administration to consider this while they work on legislation regarding drug pricing. Other actions are